Literature DB >> 11251120

Structure of an extracellular gp130 cytokine receptor signaling complex.

D Chow 1, X He , A L Snow, S Rose-John, K C Garcia.   

Abstract

The activation of gp130, a shared signal-transducing receptor for a family of cytokines, is initiated by recognition of ligand followed by oligomerization into a higher order signaling complex. Kaposi's sarcoma-associated herpesvirus encodes a functional homolog of human interleukin-6 (IL-6) that activates human gp130. In the 2.4 angstrom crystal structure of the extracellular signaling assembly between viral IL-6 and human gp130, two complexes are cross-linked into a tetramer through direct interactions between the immunoglobulin domain of gp130 and site III of viral IL-6, which is necessary for receptor activation. Unlike human IL-6 (which uses many hydrophilic residues), the viral cytokine largely uses hydrophobic amino acids to contact gp130, which enhances the complementarity of the viral IL-6-gp130 binding interfaces. The cross-reactivity of gp130 is apparently due to a chemical plasticity evident in the amphipathic gp130 cytokine-binding sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251120     DOI: 10.1126/science.1058308

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  76 in total

1.  Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain.

Authors:  J N Varghese; R L Moritz; M-Z Lou; A Van Donkelaar; H Ji; N Ivancic; K M Branson; N E Hall; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

Review 2.  Cytokine homologs of human gammaherpesviruses.

Authors:  Sang-Hoon Sin; Dirk P Dittmer
Journal:  J Interferon Cytokine Res       Date:  2011-12-05       Impact factor: 2.607

3.  Analysis of 4.3 kilobases of divergent locus B of macaque retroperitoneal fibromatosis-associated herpesvirus reveals a close similarity in gene sequence and genome organization to Kaposi's sarcoma-associated herpesvirus.

Authors:  Timothy M Rose; Jonathan T Ryan; Emily R Schultz; Brian W Raden; Che-Chung Tsai
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

4.  Human herpesvirus 8-encoded cytokines.

Authors:  John Nicholas
Journal:  Future Virol       Date:  2010-03       Impact factor: 1.831

5.  Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes.

Authors:  Yibin Xu; Nadia J Kershaw; Cindy S Luo; Priscilla Soo; Michael J Pocock; Peter E Czabotar; Douglas J Hilton; Nicos A Nicola; Thomas P J Garrett; Jian-Guo Zhang
Journal:  J Biol Chem       Date:  2010-05-20       Impact factor: 5.157

6.  Structural requirements for gp80 independence of human herpesvirus 8 interleukin-6 (vIL-6) and evidence for gp80 stabilization of gp130 signaling complexes induced by vIL-6.

Authors:  Daming Chen; John Nicholas
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 7.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

8.  Crystallization of a 2:2 complex of granulocyte-colony stimulating factor (GCSF) with the ligand-binding region of the GCSF receptor.

Authors:  Eijiro Honjo; Taro Tamada; Yoshitake Maeda; Takumi Koshiba; Yasuko Matsukura; Tomoyuki Okamoto; Matsujiro Ishibashi; Masao Tokunaga; Ryota Kuroki
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-07-30

Review 9.  Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.

Authors:  Emily Cousins; John Nicholas
Journal:  Recent Results Cancer Res       Date:  2014

10.  Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6.

Authors:  Daming Chen; Gordon Sandford; John Nicholas
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.